How We Operate
Optimizing Our Operations
By design, InteguRx Therapeutics has elected to retain a ‘lean’ infrastructure, in order to preserve capital and delay dilution of equity until we have achieved ‘proof of concept’ with one of our lead products. Accordingly, our Leadership Team, comprised of our two Co-Founders, have advanced the company’s efforts using our own capital, supplemented by non-dilutive grant funding.
InteguRx Therapeutics Core Competencies
-
First and foremost, our Chief Scientific Officer is the source of our ‘secret sauce’. Dr. Kydonieus has designed the creative approaches which have enabled us to achieve the requisite degree of human skin permeation to support delivery of therapeutic doses of our drug targets through the dermis and ultimately to the circulation. We have been able to project this delivery using the well-validated in vitro model known as the Franz Diffusion Cell, utilizing human cadaveric skin as the barrier membrane; this model has been demonstrated to have a high degree of predictive value for what will be achieved in vivo once we enter the clinical phase of development.
-
Our Chief Executive Officer, who currently doubles as our Chief Medical Officer, brings the clinical expertise to recognize important therapeutic targets which suffer from one or more currently unmet medical needs, and where facilitation of the transdermal route of administration could potentially solve each of those problems. Beyond this, Dr. Shangold’s multi-decade immersion in Clinical Research and Regulatory Affairs enables the smart design of efficient Clinical Investigational Plans for each of our products, and ultimately the oversight of those programs (executed by thoughtfully-selected Contract Research Organizations), all the way through to regulatory submission and approval as needed.
External Collaborations
Beyond these core skills and knowledge bases, we turn for assistance to a small cadre of trusted collaborators. These include highly experienced entities that perform the critical services fundamental to our success.
-
Our consistent collaborator over the past decade has been Dr. Hock Tan, Principal/Director of Ventures & Technologies at Bionex Pharmaceuticals. Dr. Tan has more than 20 years of R&D experience in pharmaceutical formulation and medical device technologies, particularly in the realm of transdermal, transmucosal, and thin-film drug delivery systems. Bionex has been awarded several SBIR grants over the years. Dr. Tan and his staff perform all of our basic laboratory bench research, including creating the formulations engineered by Dr. Kydonieus, and performing the requisite studies which follow, including solubility, human in vitro skin permeation, patch component compatibility, patch design and specifications, and stability. The quality of his work is always excellent, with closely-congruent replicates, and is always reproducible.
-
Our IP portfolio has been built and fortified by the well-known legal firm Baker Hostetler (who acquired Woodcock Washburn, our original IP firm). Since our inception, our team of talented attorneys has been led by Jeffrey Rosedale, with the subsequent additions of Stephanie Lodise and then Tracy Palovich.
-
We have consulted with a multitude of clinical and basic scientists over the years and have benefited greatly from their ideas and suggestions. As we move closer to IND stage with our two lead products, we will likely establish a standing Scientific Advisory Board.
As we move forward, we will engage the services of additional resources as need dictates, initially on a contractual basis, and when it makes sense, by expanding our employee force to include expertise in, among other disciplines, business development, strategic marketing, and capital raising.
